Colorado voters approved a measure to make the medical use of ‘magic mushrooms’ legal, paving the way for its use in treating several mental health disorders
Your search for psilocybin returned 16 results
Percentage of heavy drinking days reduced with psilocybin combined with psychotherapy versus active placebo plus psychotherapy
This week Pfizer seeks Emergency Use Authorization for their COVID-19 oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I drug in the US.
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram
Reductions in anxiety, depression in cancer-related psychiatric distress sustained at 3.2 and 4.5 years.
The FDA has granted Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder.
The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.
The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.